Death of minor Kevin Acosta exposes failures in drug supply at Nueva EPS, says the Attorney General's Office
The minor went almost two months without receiving essential medication for his treatment Photo: EL TIEMPO / Private archive
TL;DR
- The death of Kevin Arley Acosta Pico was attributed to failures in the delivery of his treatment, specifically the lack of the drug Emicizumab for hemophilia.
- The child suffered from hemophilia and his condition worsened due to the delay in receiving the medication, which he went without for approximately two months.
- The interruption in treatment was caused by Medicarte's suspension of drug delivery due to non-payment by Nueva EPS.
- IPS Integral, which was supposed to take over care, also failed to provide services due to a lack of funds from Nueva EPS.
- The Attorney General's Office found that the minor was not assigned to an IPS at the time of his death, leaving his medical care without institutional support.
- Approximately 2,000 patients previously assigned to Medicarte and Integral may also be at risk due to similar service disruptions.
- The Attorney General's Office will forward the case to the Fiscalía General de la Nación for potential criminal investigations.
- A disciplinary investigation has been launched against Óscar Galvis, the interventor of Nueva EPS, for his potential responsibility.